Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Precision Biologics has completed accrual to its Phase 2 study utilizing its novel monoclonal antibody Ensituximab (NPC-1C).
Subscribe to our email newsletter
NPC-1C targets a unique member of the MUC family that is specific to colorectal cancer with little reactivity to normal cells. Encouraging overall survival (OS) data was observed in the initial dose escalation phase in patients with chemotherapy refractory metastatic colorectal cancer.
Patients in the preliminary study had an OS of 10.4 months, comparing favorably to the historical control for a similar population of patients (5.0 months)
These results led to the current, statistically powered Phase 2 design of the study in 47 patients with colorectal cancer with a primary endpoint to increase overall survival after treatment with NPC-1C.
Results of the Phase 2 study will be presented by Philip M. Arlen, MD, President and CEO of Precision Biologics at the Oxford Global 16th Annual Drug Summit and 3rd Annual Discovery Chemistry and Drug Designs Conference held on June 8th-9th, 2015 in Berlin, Germany.
Founded in February 2012 and commencing business in late September 2012, Precision Biologics, is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer.
Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials.